Market closed
MyMD Pharmaceuticals Inc./$TNFA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About MyMD Pharmaceuticals Inc.
TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms, Isomyosamine and Supera-CBD. Isomyosamine is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B. The company has one reportable segment focused on Isomyosamine.
Ticker
$TNFA
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
2
ISIN
US62856X2018
Website
TNFA Metrics
BasicAdvanced
$2M
-
-$11.15
2.48
-
Price and volume
Market cap
$2M
Beta
2.48
52-week high
$0.45
52-week low
$0.16
Average daily volume
2.5M
Financial strength
Current ratio
1.404
Quick ratio
1.271
Total debt to equity
0.072
Management effectiveness
Return on assets (TTM)
-27.56%
Return on equity (TTM)
-169.93%
Valuation
Price to book
0.07
Price to tangible book (TTM)
-0.77
Price to free cash flow (TTM)
-0.046
Growth
Earnings per share change (TTM)
109.19%
3-year earnings per share growth (CAGR)
-24.22%
TNFA News
AllArticlesVideos
TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 Agonists
Business Wire·6 days ago
TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development
Business Wire·3 weeks ago
TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society's Spring Meeting 2025
Business Wire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for MyMD Pharmaceuticals Inc. stock?
MyMD Pharmaceuticals Inc. (TNFA) has a market cap of $2M as of May 14, 2025.
What is the P/E ratio for MyMD Pharmaceuticals Inc. stock?
The price to earnings (P/E) ratio for MyMD Pharmaceuticals Inc. (TNFA) stock is 0 as of May 14, 2025.
Does MyMD Pharmaceuticals Inc. stock pay dividends?
No, MyMD Pharmaceuticals Inc. (TNFA) stock does not pay dividends to its shareholders as of May 14, 2025.
When is the next MyMD Pharmaceuticals Inc. dividend payment date?
MyMD Pharmaceuticals Inc. (TNFA) stock does not pay dividends to its shareholders.
What is the beta indicator for MyMD Pharmaceuticals Inc.?
MyMD Pharmaceuticals Inc. (TNFA) has a beta rating of 2.48. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.